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Individuals who suffer from schizophrenia often show a marked deficit in recognition
of emotional facial expressions, as part of broader impairment of social cognition.
Research has shown that recognition of negative emotions, specifically fear recognition,
is particularly impaired among patients with schizophrenia. Recently we reported that
intranasal administration of OT (IN OT) increased the ability to correctly recognize fear
in a group of healthy men. The aim of the current study was to examine the effects of
IN OT administration on fear recognition among patients with schizophrenia. Based on
previous research, we also sought to examine a possible selective effect of OT dependent
on baseline performance, hypothesizing that IN OT would have a greater enhancement
effect on less proficient individuals. It was thus hypothesized that patients will show
more improvement in fear recognition following the administration of IN OT as compared
to controls. Sixty six participants (31 schizophrenia patients, 35 healthy controls) were
enrolled in the current study. All participants received treatment of a single dose of
24 IU IN OT and an equivalent amount of placebo, 1 week apart. The participants’ ability
to accurately recognize fear and happiness was evaluated using a face morphing task.
Overall, as a group, both patients and healthy control participants were more accurate in
recognizing fearful facial expressions, but not happy faces, following IN OT administration,
as compared to their performance following placebo. IN OT did not differentially affect
emotion recognition in patients and healthy controls. Yet, the results indicated a selective
effect for IN OT, in which the hormone improves fear recognition only among individuals
whose baseline performance was below the median, regardless of their psychiatric
status.
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INTRODUCTION
Individuals who suffer from schizophrenia often show a marked
and stable deficit in many aspects of social cognition, such as
emotion recognition, social perception, and empathy (Brune,
2005; Green et al., 2005, 2012; Derntl et al., 2009; Kohler et al.,
2010; Achim et al., 2011). These deficient abilities are consistent
over time, apparent in the prodrome to psychosis (Amminger
et al., 2012a,b; Thompson et al., 2011, 2012) and seriously impede
social competence (Brune et al., 2007; Smith et al., 2012). Indeed,
they have a tremendous impact on overall proficiency and reha-
bilitation results, leading Wible (2012) to define this illness as
one of “social communication.” Furthermore, social cognition
has been suggested as a mediator between neurocognition and
functional outcome, demonstrating once more this domain’s
prominent role in this disease (Green et al., 2012).
Numerous studies of schizophrenic patients over the last
decades have shown a consistent and marked impairment in
emotion recognition via facial expression (Pinkham et al., 2007;
Kohler et al., 2010), prosody (Edwards et al., 2001, 2002; Hoekert
et al., 2007; Roux et al., 2010; Jahshan et al., 2013), and whole
body movements (Singh et al., 2011). Furthermore, impairments
in emotion recognition have been shown to predict functional
outcome for schizophrenic patients (Irani et al., 2012).
Facial emotion recognition has been widely investigated in the
context of schizophrenia, due to its correlation with global func-
tioning, as well as the fact that patients with schizophrenia show
a consistent impairment in this domain. Furthermore, previous
studies have suggested that compared with the recognition of
other emotions (i.e., happiness), patients with schizophrenia may
have a selective dysfunction in the perception of negative emo-
tions such as fear (Kohler et al., 2003; Hofer et al., 2009; Huang
et al., 2011; Amminger et al., 2012a,b; Chen et al., 2012). For
example, Chen et al. (2012) reported a deficit in fear discrimina-
tion in patients with schizophrenia compared to healthy control
subjects, as well as a significant correlation between fear dis-
crimination and Positive and Negative Symptoms of Schizophrenia
(PANSS) negative symptoms scores. A specific impairment in
fear recognition was also evident in a group of patients with
schizophrenia (Leung et al., 2011), as well as in the studies
of Norton et al. (2009) and Amminger et al. (2012a,b). These
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findings suggest that while fear recognition may not encom-
pass the whole social cognition deficit shown by patients with
schizophrenia, it might have a considerable importance with
respect to this disorder. Impaired fear recognition has been asso-
ciated with maladaptive aggressive behavior in schizophrenia
(Weiss et al., 2007), as well as in other socially impaired popula-
tions (Marsh and Blair, 2008). Earlier, Marsh et al. (2007) showed
evidence to support that fear recognition in healthy participants
is strongly associated with prosocial behavior. Thus, it is possible
that improving fear recognition in schizophrenia may be valuable
in diminishing their levels of social impairment and improve their
daily interactions.
We have recently developed a novel explanatory model of
social impairments in schizophrenia that focuses on dysfunction
in the oxytocinergic system (Fischer-Shofty et al., 2013). Oxytocin
(OT) has repeatedly been shown to improve different facets of
social cognition, such as emotion recognition (Fischer-Shofty
et al., 2010; Marsh et al., 2010; Lischke et al., 2012a,b; Van and
Bakermans-Kranenburg, 2012), empathy (Domes et al., 2007a,b;
Bartz et al., 2010; Krueger et al., 2013), and trust (Kosfeld et al.,
2005; Theodoridou et al., 2009). Recently, Lischke et al. (2012a,b)
reported that intranasal administration of OT (IN OT) increased
participants’ ability to detect emotion in facial expressions, as
compared to a placebo group. Schulze et al. (2011) demon-
strated a similar effect of enhanced emotion detection following
IN OT administration, as expressed in more accurate perfor-
mance on tasks involving emotion recognition of masked facial
expressions. Consistent with these studies, we previously reported
that intranasal administration of OT specifically improved accu-
rate recognition of fearful facial expressions (Fischer-Shofty et al.,
2010). An improvement in emotion recognition, and that of fear
in particular, following OT administration was also evident in the
recent meta-analysis of Shahrestani et al. (2013), adding further
evidence for the possible role of OT in fear recognition.
Thus, the oxytocinergic system is a promising neuromodulator
of emotion recognition that may have the potential to normal-
ize the social dysfunction seen in schizophrenia. Indeed, studies
have shown abnormal levels of OT in the plasma of patients with
schizophrenia (Goldman et al., 2008), as well as in their cere-
brospinal fluid (CSF) (Linkowski et al., 1984; Beckmann et al.,
1985; Legros et al., 1992). Moreover, OT levels have been signifi-
cantly associated with social functioning of patients (Rubin et al.,
2010; Sasayama et al., 2012), and recent studies have linked vari-
ations in the OXTR gene to schizophrenia (Souza et al., 2010a,b;
Montag et al., 2012a,b). In addition, previous studies suggest an
antipsychotic influence of OT among individuals who suffer from
schizophrenia (Bujanow, 1974; Feifel and Reza, 1999; Caldwell
et al., 2009; Feifel et al., 2010; Pedersen et al., 2011; Macdonald
and Feifel, 2012). Recently Feifel et al. (2012) reported a benefi-
cial effect for IN OT on verbal memory in schizophrenia. With
respect to social cognition, OT was reported to improve emotion
recognition among schizophrenic patients (Averbeck et al., 2012),
as well as theory of mind and social judgments (Pedersen et al.,
2011).
In view of the role of OT in facial emotion recognition (espe-
cially fear recognition), as well as the established deficit of patients
with schizophrenia in emotion recognition, we sought to examine
the effect of IN OT on fear recognition in individuals with
schizophrenia. In light of our previous research (Fischer-Shofty
et al., 2010) demonstrating that a single dose of IN OT signifi-
cantly improved fear recognition among healthymen, we hypoth-
esized that patients with schizophrenia would show improved fear
(but not happiness) recognition following the administration of
IN OT. Second, we sought to compare the effect of IN OT on
emotion recognition in patients to that of healthy control indi-
viduals. Moreover, based on earlier results exhibiting a selective
effect of IN OT on less socially competent individuals (Bartz et al.,
2010), we hypothesized that the effect of INOT administration on
fear recognition would be stronger among patients compared to
among healthy controls.
METHODS
PARTICIPANTS
Thirty patients diagnosed with schizophrenia (27 men and
3 women, mean age = 31.8 years, SD = 6.53) and thirty-five age-
matched healthy individuals (32 men and 3 women, mean age =
29.49 years, SD = 5.59) participated in the current experiment,
all of them were native Hebrew speaking. Two senior psychia-
trists diagnosed the patients according to the DSM-IV criteria
by means of structured clinical interviews. In addition, all of
the participants were screened by a trained clinician for various
psychopathologies using the Mini International Neuropsychiatric
Interview (M.I.N.I.) (Sheehan et al., 1998). Exclusion criteria
were physical illnesses (including arrhythmia, psychiatric condi-
tions, any neurological condition, and head injury); IQ below
75; disturbances in visuomotor coordination; and alcohol or
drug abuse. The participants were outpatients and day-hospital
patients receiving stable doses of relevant medication (first gen-
eration and second generation antipsychotics, benzodiazepines,
anticholinergic drugs). All of them gave their oral and signed con-
sent. All participants were instructed to avoid using psychotropic
substances (e.g., caffeine and nicotine) for at least 12 h prior
to the experiment. The study was approved by Israel’s National
Institutional Review Board as well as by the Helsinki commit-
tee of the Shalvata Mental Health Center, and was registered as
a clinical trial at the NIH website (code number NCT00813436).
Patients and controls were age matched, and all received financial
compensation for participating in the study.
CLINICAL ASSESSMENT
As shown in Table 1, the patients were clinically assessed by a
trained psychologist using the PANSS, developed by Kay et al.
(1987) to evaluate positive symptoms, negative symptoms and
general psychopathology (occurrence and severity), and the
Clinical Global Impression scale (CGI), used to estimate the sever-
ity of patients’ illness. All of the participants completed the
vocabulary subtest and the abstract test of the Shipley Institute of
Living Scale (Shipley, 1940) to assess their intellectual abilities. For
technical reasons, only 42 subjects overall completed the Shipley
scale.
TREATMENT ADMINISTRATION
In the current study we employed a double-blind within-subject
crossover design. All participants participated in two sessions, one
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Table 1 | Demographic and clinical characteristics of patients with
schizophrenia and controls.
Patients with Control Statistics p
schizophrenia participants
(n = 31) (n = 35)
Age (years) 31.80 (6.53) 29.49 (5.59) t(63) = −1.541 0.128
Gender (males:
females)
27:3 32:3
Education
(years)
12.20 (1.97) 15.09 (2.02) t(63) = 5.804 0.000
Illness duration
(years)
11.02 (6.73)
Number of
hospitalizations
3.48 (3.34)
PANSS total
score
68.55 (12.41)
PANSS positive
symptoms
15.59 (3.92)
PANSS negative
symptoms
18.48 (4.56)
PANSS general
psychopathology
34.10 (6.59)
CGI 4.63 (0.81)
Shipley
vocabulary
25.73 (7.47) 30.50 (6.91) t(40) = 1.906 0.064
Shipley abstract 10.73 (4.33) 14.00 (3.30) t(40) = 2.637 0.024
after IN OT administration and the other 7 days later, following
placebo administration. Half of the participants were randomly
assigned to receive IN OT in the first session, and half began
with placebo administration. In both sessions the behavioral tasks
began 45min after substance administration. IN OT adminis-
tration included three puffs of syntocinon spray (Novartis) in
each nostril (each puff containing 4 IU, a total of 24 IU). Placebo
administration involved three puffs in each nostril from a simi-
lar looking spray bottle that contained all the inactive ingredients
except for OT. IN OT dosage and waiting time corresponded
to those used in previous experiments investigating the effect of
intranasal administration ofOT on human behavior (Kirsch et al.,
2005; Kosfeld et al., 2005; Domes et al., 2007a,b, 2010; Guastella
et al., 2008).
ASSESSMENT OF FACIAL EMOTION EXPRESSION RECOGNITION: THE
FACEMORPHING TASK
The facemorphing task was designed to test recognition of emo-
tional facial expressions. In the task, gradually changing facial
expressions are portrayed, beginning with a neutral expression
that continuously evolves into an emotional expression. The faces
were gray-scale standardized computer-generated photographs
of six Caucasian participants, whose facial expressions varied
to express happiness or fear. The face stimuli included the eye
and nose regions, while the mouth region was masked. The
participant’s task was to correctly identify the emotional facial
expression as soon as possible. The facemorphing task was used
in view of its advantage in mimicking true emotional facial
expressions, which gradually appears in the context of interper-
sonal interaction.
The face stimuli were images of three men and three women
from the Ekman series (Ekman and Friesen, 1976). Each face
stimulus was positioned within a rectangular frame measuring
6.1 × 8.9 cm, subtending 5.0 × 7.3◦ of visual angle at a 70-cm
viewing distance (173 × 251 pixels on a 256 gray-level scale).
We used graphic image morph software (Face Morph Lite 2.0)
to generate gradually evolving emotional facial expressions, from
neutral to emotional expression. The emotional facial expression
recognition task included twelve stimuli (six stimuli of each emo-
tion, e.g., fear and happiness), generated by e-prime 2.0 software.
The stimuli were presented at a frame ratio of 10 fps (each frame
was presented for 100ms) and included 100 frames, for a total of
10 s. In the task, participants were asked to press the spacebar key
as soon as they recognized an emotion in the gradually changing
expression. Immediately after pressing the spacebar key, they were
asked to report which emotion they recognized from a list of six
basic emotions (happiness, sadness, anger, fear, disgust, and sur-
prise). Reaction time and frame onset were recorded as dependent
variables.
ASSESSMENT OF MOOD
In the current study we used an adapted version of the Depression
Adjective Check Lists (DACL; Lubin, 1965) to evaluate partic-
ipants’ general mood following administration of each of the
substances (IN OT and placebo). The DACL is a self-report
instrument that includes a list of 32 adjectives describing vari-
ous mood states. Participants were asked to choose the words on
the list that best describe their current mood. We calculated the
number of positive and negative adjectives each participant chose
during each session.
STATISTICAL ANALYSES
Analyses were conducted using SPSS (version 17). To assess
treatment effect in patients and in controls, repeated mea-
sures ANOVA was used. Follow-up t-tests (with Bonferonni
corrections) were conducted in order to further explore sim-
ple effects. Moreover, a regression model was used in order
to examine the possible relationship between baseline perfor-
mance level of fear recognition and the amount of improvement
following IN OT administration. Once again, follow-up t-tests
were conducted in order to further examine significant effects.
Bonferonni corrections were used to control for multiple compar-
isons, for both the repeated measure ANOVA and the regression
model.
RESULTS
Independent-sample t-tests were employed to identify the demo-
graphic and clinical characteristics of both groups, as well as to
evaluate group differences (see Table 1).
GENERAL EFFECTS OF IN OT ON MOOD
A 2 × 2 × 2 repeated measures ANOVA indicated no overall
treatment effect [F(1, 60) = 0.038, p = 0.846] or interaction of
mood type (sadness, happiness, lack of energy, depressed, calm,
etc.) by treatment [F(7, 54) = 1.864, p = 0.094] for mood ratings.
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The three-way interaction (treatment, mood type, group) was not
significant, [F(7, 54) = 1.597, p = 0.156], further confirming that
IN OT did not have a differential effect on the mood of patients
and controls. There was a general group effect [F(1, 60) = 7.331,
p = 0.009], demonstrating an overall difference in mood rat-
ings between healthy controls and patients. Although patients
[Mean = 4.49 (SD = 1.22)] and control participants [Mean =
4.77 (SD = 0.96)] did not differ on their positive mood ratings,
patients with schizophrenia had higher ratings of negative mood
[Mean = 2.65 (SD = 1.22)] as compared to controls [Mean =
1.83 (SD = 0.81)].
IN OT AND EMOTIONAL FACIAL EXPRESSION RECOGNITION
To examine the interaction among treatment, emotional facial
expression, treatment order and group membership, a four-way
(2 × 2 × 2 × 2) repeated measures ANOVA (with Bonferonni
corrections) was conducted, with type of treatment adminis-
tered (IN OT, placebo) and emotional facial expression (fearful,
happy) as within-subjects factors and treatment order (IN OT
first, placebo first) and group membership (patients, controls)
as between-subjects factors. As shown in Figure 1, a signifi-
cant emotional facial expression effect was evident [F(1, 61) =
164.88, p = 0.0001], partial η2 = 0.730, indicating that partici-
pants across groups were better at recognizing happiness [Mean=
82.4 (SD = 0.018)] than fear [Mean = 52.73 (SD = 0.026)]. In
addition, a significant group effect was found [F(1, 61) = 6.251,
p = 0.015], partial η2 = 0.102, indicating that patients scored
lower on the task [Mean = 62.32 (SD = 0.032)] as compared to
controls [Mean = 72.06 (SD = 0.0205)]. Moreover, a significant
interaction between treatment and emotional facial expression
was found [F(1, 61) = 5.091, p = 0.028], partial η2 = 0.077, indi-
cating a differential effect of IN OT and placebo treatments on
recognition of fearful facial expressions as opposed to happy
expressions for all participants.
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FIGURE 1 | Repeated measures analysis shows a significant
interaction between treatment (OT/placebo) and emotional facial
expression (fear/happiness), indicating a differential effect of OT and
placebo treatments on recognition of fearful facial expressions, as
opposed to happy expressions for all participants. Separate repeated
ANOVA indicated significant treatment effect only for fear recognition (∗),
but not for the recognition of happiness (∗p < 0.05).
To further examine the significant interaction between treat-
ment and emotional facial expression, we conducted follow-up
paired samples t-tests, which indicated that while there was no
significant difference [t(64) = −0.88 ns] between accuracy lev-
els for recognition of happy facial expressions following IN OT
administration [Mean = 81.11 (SD = 20.45)], as compared to
following placebo administration [Mean = 83.69 (SD = 17.64)],
a significant difference [t(64) = 2.35, p = 0.022] was evident for
recognition of fearful facial expressions. The accuracy level for
recognition of fear following IN OT administration [Mean =
56.17 (SD = 24.65)] was significantly higher than accuracy levels
following placebo administration [Mean = 49.29 (SD = 23.59)],
Cohen’s d = 0.292.
Moreover, the ANOVA described before did not reveal any sig-
nificant treatment effect [F(1, 61) = 1.238, p = 0.270], indicating
no general difference in emotion recognition following IN OT
administration as compared to placebo administration. No sig-
nificant interactions were found between treatment and group
membership (schizophrenic patients, healthy control) [F(1, 61) =
0.849, p = 0.360], treatment and order of treatment adminis-
tration [F(1, 61) = 0.156, p = 0.694], emotional facial expression
and group membership [F(1, 61) = 1.915, p = 0.171] or emo-
tional facial expression and order of treatment administration
[F(1, 61) = 0.709, p = 0.403]. In addition, the three-way inter-
action of treatment × emotional facial expression × treatment
order was not significant [F(1, 91) = 1.966, p = 0.166], nor was
the three-way interaction of treatment × emotional facial expres-
sion × group membership [F(1, 61) = 0.529, p = 0.470]. Finally,
the four-way treatment × emotional facial expression × group
membership × treatment was also not significant [F(1, 61) =
0.112, p = 0.739].
In order to check whether our non-significant interaction
results were due to a lack of statistical power, we conducted post-
hoc power analyses using GPower (Erdfelder et al., 1996) with
power (1 − β) set at 0.80 and α = 0.05, two-tailed. This showed
us that total sample sizes would have to increase up to N = 168,
in order the interaction effect to reach statistical significance at
the 0.05 level.
In addition, we reanalyzed the data without female sub-
jects (3 from the patients’ group and 3 from the healthy con-
trol group, 6 overall). The four-way (2 × 2 × 2 × 2) repeated
measures ANOVA indicated that although the main effects of
emotional facial expression [F(1, 55) = 155.06, p = 0.0001], par-
tial η2 = 0.738, and group [F(1, 55) = 5.19, p = 0.027], partial
η2 = 0.086, were significant, the interaction between treatment
and emotional facial expression was only marginally-significant
[F(1, 55) = 3.93, p = 0.052], partial η2 = 0.067.
To confirm that intellectual abilities did not affect the perfor-
mance in the task, we conducted a repeated measures ANCOVA,
using both years of education and intelligence (Shipley score) as
covariates in the whole sample, as well as using treatment order
(IN OT first, placebo first) and groupmembership (patients, con-
trols) as between-subjects factors. This analysis indicated that
the interaction between treatment and emotional facial expres-
sion remains significant [F(1, 36) = 6.44, p = 0.016], partial η2 =
0.152, suggesting that the years of education and intelligence
level as measures by the Shipley test do not affect the IN OT ×
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emotional facial expression recognition interaction, but rather
improves it.
In regard to reaction time, we conducted a four-way (2 × 2 ×
2 × 2) repeated measures ANOVA to examine the relationship
between treatment, emotional facial expression, treatment order,
and group membership. A significant emotional facial expres-
sion effect was evident [F(1, 52) = 64.14, p < 0.0001], partial
η2 = 0.552, indicating that subjects’ reaction time while fac-
ing fear [Mean = 2089.1 (SD = 507.59)] was higher than while
recognizing happiness [Mean= 1537.25 (SD = 669.66)]. In addi-
tion, a significant group effect was evident [F(1, 52) = 14.625,
p < 0.0001], partial η2 = 0.220, indicating that patients’ reac-
tion time overall was higher [Mean = 2083.11 (SD = 460.32)]
as opposed to healthy control group [Mean = 1581.81 (SD =
413.08)]. No interaction between this two factors was evident
[F(1, 52) = 0.586 ns].
As in previous studies that found a differential drug effect
among participants with lower performance (Kimberg et al.,
1997; Mattay et al., 2000; Farah et al., 2009), we sought to examine
the possibility that IN OT has a differential effect on individu-
als, depending on their baseline abilities. To examine this possible
effect, we conducted a regression analysis using the difference
in performance between IN OT and placebo administration in
fear recognition. The independent variables were participants’
performance following placebo administration as a measure of
baseline ability and order of treatments (OT/placebo first). Given
our hypothesis regarding a greater enhancement effect of IN OT
among participants whose performance on the task was poor, the
prediction tested in this analysis was that lower placebo perfor-
mance would be significantly associated with greater drug effect,
and the p-values would be one-tailed accordingly. The regression
analysis showed that placebo performance predicted the size of
the drug effect, R Square = 0.205, p < 0.001. The direction of the
relationship was as predicted: enhancement effects were larger for
individuals whose performance was lower. Thus, we divided the
participants into two groups based on the median of their base-
line (placebo) performance for fear recognition (median = 0.5):
below-median performance and above-median performance. To
investigate the difference between the two groups, we conducted
separate paired t-tests (with Bonferonni corrections) for each
group, comparing their fear-recognition performance following
OT administration to that following placebo administration. As
shown in Figure 2, a significant difference was evident only
for the below-median group [t(23) = 4.575, p = 0.0001], indi-
cating that participants whose baseline performance was below
the median performed significantly better following IN OT
administration [Mean = 43.88 (SD = 25.29)] as compared to
placebo [Mean = 23.58 (SD = 13.67)], Cohen’s d = 1.056. The
above-median performance group did not show a similar signif-
icant difference [t(23) = −0.296 ns] between IN OT administra-
tion [Mean = 63.37 (SD = 21.47)] and placebo administration
[Mean = 64.34 (SD = 12.41)]. In order to examine the possi-
ble moderating role of psychiatric status in the context of the
described regression model, we performed a moderated regres-
sion, using the group factor (patients/control) as the moderating
factor (mediator), according to Baron and Kenny (1986)’s model.
No significant relationship was found between the regression
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FIGURE 2 | Separate paired t-tests reveal that participants whose
basic fear recognition ability was below the median were significantly
improved in fear recognition following OT administration, as opposed
to their performance following placebo administration (∗∗). Conversely,
participants whose basic fear recognition ability was above the median did
not exhibit any significant difference between their OT performance and
placebo performance (∗∗p < 0.0001).
independent variable (i.e., the performance of participants in fear
recognition following placebo administration) and the mediator
(B = −2.195, p > 0.05).
DISCUSSION
The aim of the current study was to characterize the effect of
intranasal administration of OT on fear recognition in individ-
uals with schizophrenia and in healthy controls. In line with
our previous study (Fischer-Shofty et al., 2010), our results show
that indeed participants were able to detect fearful facial expres-
sions more accurately following IN OT administration regardless
of their psychiatric status (e.g., healthy vs. patients). However,
it is important to note that not all studies have found a spe-
cific improvement in the recognition of fear following IN OT
administration, and rather reported a general effect on emotion
recognition in patients with schizophrenia (Averbeck et al., 2012)
and in healthy individuals (Schulze et al., 2011; Lischke et al.,
2012a,b; Van and Bakermans-Kranenburg, 2012). Furthermore,
in contrast to Marsh et al. (2010), the current results did not
show any effect of IN OT administration on recognition of happi-
ness. Notwithstanding the importance of these studies, they were
all limited by relying primarily on still emotional faces. The task
used in the present study is highly ecologically valid as it mim-
ics the dynamics of gradual changes in facial expressions. Thus,
it is possible that the difference between previous studies and the
present study is derives from the use of different tasks of emotion
recognition.
A second goal of this study was to investigate whether IN
OT affects differently patients and controls. In contrast with
our original hypothesis, IN OT did not have a differential effect
on patients and controls. While IN OT had a general effect on
improving fear recognition, it did not change performance in
the groups separately. In the next stage we wanted to exam-
ine the differential impact of IN OT depending on individual
baseline ability of fear recognition. Our results show that IN
OT improved the performance of participants whose baseline
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performance levels in fear recognition was below the median,
while significant difference between IN OT and placebo trials was
evident in the above-median subgroup. These findings are in line
with the work of Bartz et al. (2010), who reported a selective
enhancing effect for intranasal administration of OT on empathic
accuracy. In their study, participants were rated according to the
Autism Spectrum Quotient (AQ) to determine their basic social
capability. While the performance of the more capable subgroup
(i.e., lower AQ scores) was not affected by IN OT administration,
participants with high AQ scores performed the task better fol-
lowing OT administration. These findings by Bartz, et al. suggest
a more “circumscribed” role for IN OT’s augmentation of social
salience, one that preferentially benefits those with lower baseline
capabilities. As mentioned by Bartz et al., these results are in line
with the propositionmade by Shamay-Tsoory et al. (2009) that IN
OT exerts its effect by enhancing the salience of social cues, thus
increasing their importance as sensory input. Therefore, it may be
that IN OT will mostly benefit those who have deficits in the per-
ception of valuable social signals, as is the case in schizophrenia
and other disorders.
Numerous studies have established the dominant and crucial
involvement of the amygdala in emotion recognition and par-
ticularly in fear processing (see Adolphs, 2008). More recently,
increasing evidence has linked OT to the amygdala, mainly as an
effect of activation reduction (Kirsch et al., 2005; Pittman and
Spencer, 2005; Domes et al., 2007a,b, 2010; Baumgartner et al.,
2008; Riem et al., 2012; Rupp et al., 2012), thus associating OT
and fear perception. In this regard, it is worth mentioning the
study by Huber et al. (2005), which reported an excitatory effect
for OT in a distinct part of the amygdala (central and capsular
division of the central amygdala). Findings like these suggest a
neuromodulatory role for OT in amygdala and brainstem cir-
cuits (see Stoop, 2012 for recent review) which may underlie
OT’s ability to increase the accurate perception and interpreta-
tion of survival-related social cues (i.e., facial expressions of fear)
(Fischer-Shofty et al., 2010; Labuschagne et al., 2010; Lischke
et al., 2012a,b). While OT seems to be useful in heightening
one’s attention to social cues (Shamay-Tsoory et al., 2009), which
might be helpful for individuals who exhibit impaired social
attention, it is also worth considering the ramifications of exag-
gerated social salience. These latter effects may be important in
individuals with a maladaptive, hypervigilant social perception
system, as can be seen in Borderline personality disorder (Fertuck
et al., 2009; Bartz et al., 2011; Frick et al., 2012). Our results
are linked to previous data indicating the beneficial effect of IN
OT administration on social cognition in schizophrenia. They
are also in line with previous studies that reported an associa-
tion between endogenous levels of OT and social cognition in
schizophrenia (Goldman et al., 2008; Rubin et al., 2010; Sasayama
et al., 2012), those reporting links between OXTR genes and
schizophrenia (Souza et al., 2010a,b; Montag et al., 2012a,b),
as well as studies examining the effect of intranasal adminis-
tration of OT on social cognition in schizophrenia as a single
dosage (Averbeck et al., 2012; Goldman et al., 2011) or as a more
long-term treatment (Feifel et al., 2010; Pedersen et al., 2011;
Modabbernia et al., 2013). These findings further reinforce the
hypothetical role of the oxytocinergic system in the epidemiology
of this disorder and suggest OT as a possible therapeutic target in
schizophrenia.
It is important to note that recent studies suggest a dissociable
role for IN OT in males and females. Domes et al. (2010) reported
a different neural activation pattern, including the amygdala, fol-
lowing IN OT administration in women, as opposed to men.
Similarly, Lischke et al. (2012a,b) have found an increased acti-
vation response of women’s amygdala following IN OT admin-
istration, as opposed to the known reduced activation of the
amygdala in men (Kirsch et al., 2005). The sample in the cur-
rent study included both men and women (with the majority of
men), and while our reanalysis of the data using only male partic-
ipants remained marginally-significant, future studies should use
larger samples of women andmen and take into consideration sex
differences in the context IN OT.
The study has some limitations that should be taking into con-
sideration. One relates to sample size and sample composition.
The participants in the current study were healthy individuals
and patients with schizophrenia, while other psychiatric popu-
lations were not represented in our cohort. Therefore, general
implications regarding the effects of intranasal administration of
OT on fear recognition should be made with caution. Moreover,
our power analysis suggests that a larger sample (more than 150
participants) could provide significant results regarding the con-
tribution of psychiatric status to the reported results. Thus, future
studies may examine the study hypotheses using larger samples in
order to provide the basis for stronger conclusions. Our results
show a general effect of IN OT on fear recognition, while no
significant effect was evident in either the patients group or in
the healthy control group alone. Therefore it is impossible to
infer whether the effect of oxytocin is driven by the patients or
by the healthy controls. Moreover, as our regression model indi-
cates, it cannot be concluded which of the groups (i.e., patients or
healthy controls) is responsible for these results. In view of the
fact that several psychiatric disorders show meaningful deficits
in emotion recognition, future studies should further examine
this possible effect in larger groups, as well as for other types
of social inadequacy seen in mental illnesses such as anxiety,
depression, and autism spectrum disorders. In regard to study
cohort, future studies should address important issues in the con-
text of schizophrenia, such as illness stage, medication type, and
comorbidity, which could potentially affect the results. Finally,
it should be noted that in the current study we used only two
basic emotions, happiness, and fear. Therefore, any generaliza-
tion of the effect of IN OT on emotion recognition, other than
those who were evaluated in the study must be also done with
caution.Moreover, it has been suggested that fearful facial expres-
sions are better recognized in masked faces that lack the mouth
region, as opposed to facial expressions of happiness. Thus, we
cannot rule out the effect of the masked stimuli used in the
current study, which could have had an effect on our results.
Another aspect of the study design that could affect our results
involves the use of performance following placebo administra-
tion as baseline performance. While the use of placebo trials has
been reported in previous studies of different drugs and cogni-
tion (Farah et al., 2009), the design could be improved by having
a second measure of performance following placebo to prevent
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the use of our predictor variable in calculating the drug effect.
Moreover, differences between patients and healthy control par-
ticipants in education level, as well as intelligence level as
assessed by the Shipley test, may also serve as study limitations.
Although our controlled analysis did not blemish the original
result of interaction between treatment and emotion recogni-
tion, nonetheless, future studies which will control for these
factors a priori could have stronger results. Therefore, we can-
not confidently conclude that IN OT is solely responsible for the
apparent difference in emotion recognition. Future studies should
rule out the effect of education and intelligence levels on these
abilities by employing a matched-group design regarding these
factors.
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